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Abstract
Inflammatory responses can vary depending on a myriad of factors including: 1) the initiating 
stimulus or trigger, 2) the cell types, involved in the response, and 3) the specific effector 
cytokine-chemokine milieus produced. The compilation of these and other factors in a given 
mechanistic context is sometimes referred to as the “inflammome”. Humans and other higher 
order mammals have evolved (over time) several discrete inflammomes to counter the effects of 
pathogens. However, when these inflammomes are induced inappropriately, they drive the 
development of chronic inflammatory diseases. The vast majority of biological anti-inflammatory 
treatments currently being developed are focused on the post hoc inhibition of downstream 
effectors by anti-cytokine monoclonal antibodies and receptor antagonists. This prevailing “end-
point treatment” has even directed a new disease classification paradigm, namely a cytokine-based 
disease classification, as opposed to a traditional diagnosis based on a particular tissue or organ 
system dysfunction. Although this approach has a number of advantages, it omits the processes 
that led to the generation of the inflammatory effectors in the first place. In this review, we will 
expand the cytokine-based disease taxonomy into an inflammome-based taxonomy that includes 
interventions that subvert a priori cytokine development that can complement post hoc inhibition.
1.0 INTRODUCTION
Inflammation, to use a timeworn axiom, is a double-edged sword. Under normal 
physiological circumstances, it operates as an integral component of a defense system that 
the human body utilizes to ward off the incursion of foreign pathogens [1]. However, if 
inappropriately directed or poorly regulated, inflammation can lead to significant morbidity 
and mortality [2]. It is truly a unique circumstance within physiology that one of the greatest 
assets for developing Darwinian fitness can abruptly become one of the most significant 
contributors to tissue dysfunction, destruction, and disease.
Although the mechanisms by which inflammation develops has become more complex and 
efficient over evolutionary time, there are only but a handful of molecular signaling 
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pathways and professional immune cell types that drive inflammatory processes [3]. 
Nevertheless, the term inflammation is used very broadly, particularly as it is portrayed to 
the general public. This oversimplification has contributed to the stagnation in therapeutic 
options for patients suffering from “inflammatory” diseases, until the advent of cytokine-
specific biologicals in the 1990s [4, 5]. In reality, inflammation can vary depending on a 
myriad of factors including: 1) the initiating stimulus or trigger (e.g. pathogenic infection, 
cell injury, molecular mimicry, or inappropriate responses to a self-antigen), 2) the cell 
types, receptors, and signaling pathways involved, 3) the generation of specific effector 
cytokine and chemokine milieus, 4) temporality of the response (e.g. acute vs. chronic, or 
early vs. late phase), and 5) the type of pathology that results (e.g. systemic vs. local, tissue 
destruction vs. tissue repair). The compilation of these factors in a given mechanistic context 
is the “inflammome” [6].
Humans and other higher order mammals have, over evolutionary time, developed several 
discrete inflammomes designed to counter specific types of pathogens (Fig. 1). However, 
when these inflammomes are induced inappropriately, they drive the development of 
distinctive disease-causing effector molecules that have become the basis of many new 
interventional therapies [7]. The vast majority of biological anti-inflammatory treatments 
currently being developed are focused on the post hoc, direct inhibition of downstream 
effectors by anti-cytokine monoclonal antibodies or receptor antagonists. This prevailing 
predilection for “end-point treatment” has even directed a new approach to disease 
classification, namely, a cytokine-based disease taxonomy [8], as opposed to a traditional 
diagnosis based on a particular tissue or organ system dysfunction. Although this approach 
can be beneficial for categorizing inflammatory diseases, it omits the underlying processes 
that led to the generation of these effectors in the first place. In this review, we will focus on 
delineating not only the pathogenic sequelae of inflammation-driving effector cytokines, but 
also the distinct inflammomes that lead to their synthesis. Through this, we discuss the 
benefits of expanding the present cytokine-based disease taxonomy into an inflammome-
based disease taxonomy, while directing the focus of future therapeutic development toward 
those interventions that subvert a priori cytokine development, in addition to their post hoc 
inhibition.
2.0 THE MAJOR INFLAMMOMES
2.1 INNATE (TNF DOMINANT)
The innate immune response is composed of different cell types that respond to diverse 
endogenous or exogenous signals and mediate distinct downstream effects within minutes to 
hours of activation. However, there are at least three major cytokine milieus that can be 
generated based on all of these factors: tumor necrosis factor (TNF) dominant, interferon 
(IFN) dominant, and inflammasome dominant. The word “dominant” is used because, in 
reality, all of these responses are generated to varying degrees with any given inflammogen. 
For clinical purposes, thinking about the innate response in the context of these three major 
divisions allows one to clearly see that these milieus are generated by distinct signaling 
cascades that provide an opportunity for specific therapeutic interventions.
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A TNF dominant response can be generated by either a pathogenic infection or trauma that 
results in cell injury [9]. These initiating triggers are recognized by the innate immune 
system through pathogen associated molecular patterns (PAMPs), or in the case of cell 
injury, damage-associated molecular patterns (DAMPs) [1, 10, 11]. PAMPs, as the name 
implies, are usually structural components of bacteria, viruses, or fungi that are recognized 
through pattern recognition receptors (PRRs) on immune cells such as macrophages, 
dendritic cells, and B cells [12]. On the other hand, DAMPs are factors from host cells that 
are normally sequestered away from immune recognition, but in the face of cell injury or 
death, are released from cells. DAMPs, such as the nucleosome associated protein HMGB1, 
can be recognized by the same PRRs as PAMPs [13].
PRRs, such as the toll-like receptors (TLRs), activate two distinct signaling pathways 
following ligation, depending on which PAMP is recognized. In TNF dominated responses, 
the major contributing pathway involves activation of the MyD88 adaptor protein, which is 
activated most strongly in the context of lipopeptides (TLR1/2 or 2/6), LPS (TLR4), 
flagellin (TLR5), profilin (TLR11, 12), ribosomal RNA (TLR13), or CpG 
oligodinucleotides (TLR9) [12]. MyD88 is responsible for coupling TLR ligation to the 
activation of the pro-inflammatory transcription factor NF-κB through a complex signaling 
pathway involving interleukin-1 receptor-associated kinase (IRAK) 1 and 4, TNF receptor 
associated factor 6 (TRAF6), TAK1, IκB kinase (IKKα/β/γ), and finally poly-
ubiquitinylation and degradation of the inhibitor of NF-κB, IκBα [14]. NF-κB function 
results in the transcription of genes important for cell survival, as well as initiating a pro-
inflammatory program. Specifically, in conjunction with MAPK signaling, this leads to 
synthesis of the transcription factor activator protein 1 (AP-1), which induces transcription 
of the TNF gene. After TNF protein is produced, it exerts pleiotropic effects on the body 
including: activation of the underlying tissue endothelium which directs other immune cells 
to sites of inflammation, activation of the pro-inflammatory acute phase response proteins 
from the liver (interleukin-6, C-reactive protein, serum amyloid A, etc.), enhancement of 
phagocytosis and oxidative burst by phagocytic cells, and during prolonged or systemic 
exposure, insulin resistance, muscle wasting, and vasodilation [9, 15]. Additionally, TNF 
signaling through its receptors can lead to further activation of NF-κB, and subsequently 
more TNF production, creating a very potent and potentially dangerous cycle of activation 
[16].
TNF is produced in nearly every inflammatory disease; however, there are several in which 
TNF predominates the response, so much so that anti-TNF interventions have been 
introduced as therapies. These include inflammatory bowel diseases (Crohn’s disease and 
ulcerative colitis), rheumatoid arthritis, ankylosing spondylitis, psoriasis, several 
vasculitides including giant cell arteritis, and asthma that is refractory to other therapies [5, 
17]. Systemic TNF, via activation of the acute phase response, can also result in a “cytokine 
storm”, which leads to the initiation of systemic inflammatory response syndrome (SIRS) or 
sepsis for triggers involving bacteremia, viremia, or mass tissue damage (e.g., from 
electrocution or severe burns)[18].
Current anti-TNF therapies being used in the clinical setting include: anti-TNF monoclonal 
antibodies (infliximab, adalimumab) and soluble TNF decoy receptors (etanercept) [19, 20]. 
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However, many disease processes do not respond to anti-TNF therapy. In fact some, as in 
the case of multiple sclerosis [21], are exacerbated with anti-TNF therapy. The number of 
adverse effects of anti-TNF treatments is also growing and to date include increased risks of 
infection, autoimmune disease, and malignancy.
As anti-TNF treatment was the first biologic anti-cytokine therapy to be FDA approved (in 
1998)[22], it is not surprising that this field is also the first to realize the need for a priori 
therapeutics, exemplified by the recent wave of NF-κB inhibitors and TLR antagonists 
currently in clinical trials [23] to prevent sepsis and treat other TNF-centric inflammomes 
[24]. Some of the drugs under development for the innate/TNF-dominated inflammome are 
shown in Table I. These agents act on a range of dysregulated targets in this inflammome. 
Resatorvid acts at a very early stage by inhibiting the TLR4 receptor and inhibiting 
lipopolysaccharide-induced inflammatory mediator production [25]. Other compounds, such 
as apremilast, cool this inflammome by inhibiting intermediate steps; apremilast inhibits the 
phosphodiesterase PDE4, which promotes cellular cAMP accumulation and suppresses NF-
κB activity and inflammatory mediator production [26]. Understanding the details of this 
inflammome has helped identify novel treatments that target dysfunctional signaling 
pathways at the root of the disease.
2.2 INNATE (IFN DOMINANT)
The innate IFN dominant inflammome is initiated in a manner analogous to the TNF 
dominant inflammome (i.e. PAMP-TLR interaction); however, the ligands recognized in 
these responses are generally nucleic acids from viruses, and to a lesser extent bacteria, or 
even endogenous DNA and RNA in the context of autoimmune diseases like systemic lupus 
erythematosus. The signaling mechanisms of type-I IFN generation are complex but are 
becoming well described. Briefly, nucleic acid PAMPs are recognized by endosomal (TLR3, 
TLR7, TLR8) or cytoplasmic (RIG-I, MDA-5, STING) sensors, and converge downstream 
at the level of interferon regulatory factor 3 (IRF3) and IRF7 phosphorylation [27, 28]. IRF3 
and IRF7 act to initiate the transcription of type-I IFNs (IFNα/β/δ/ε/ω) which, like TNF, can 
enhance their own production via a positive feed-forward loop. Type-I IFNs can be made by 
most cell types, but plasmacytoid dendritic cells (pDCs) have been identified as professional 
IFNα producing cells in response to nucleic acid PAMPs [29]. The importance of pDCs in 
type-I IFN production is exemplified by the fact that they have a cell-type specific alteration 
in their signaling machinery that permits IFNα production directly after stimulation with 
TLR7 and TLR9 ligands through a TRAF3-independent mechanism involving IKKα and 
IRF7. Type-I IFNs, like TNF, also have pleiotropic effects at different levels of the immune 
system including activation of anti-viral response genes, the establishment of CXCR3-
mediated chemokine gradients via CXCL9 and CXCL10, and the enhancement of IFNγ 
production from Th1 and Tc1 T cells and NK cells [30]. Type-I IFNs can also lead to 
STAT3 phosphorylation in macrophages and Tregs which induce an anti-inflammatory 
response via up-regulation of IL-10 and PD-L1 [31].
Some diseases associated with altered type-I IFN production include SLE [32], psoriasis 
[33], multiple sclerosis (therapeutic) [34], insulin-dependent diabetes mellitus [35], 
rheumatoid arthritis (therapeutic) [36], myasthenia gravis [37], and some hematologic 
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malignancies [38]. Therapeutically, anti-IFN treatments for diseases like SLE and 
polymyositis have shown some promise in reducing symptom severity [39, 40], although 
responses in SLE was limited to a subpopulation of patients. However, inhibition of IFNα 
theoretically increases the risk of viral infections, so trials of anti-IFN therapies are carefully 
monitored and exclude patients with chronic viral infections. The anti-viral activity of type-I 
IFNs highlights the drawback of targeting effector cytokines and supports the further 
development of inflammome-targeting therapies. Interestingly, recombinant IFNβ has been 
established as a treatment for relapsing-remitting multiple sclerosis [34]. Although this 
treatment has proven to be effective for many, it can potentially exacerbate existing 
autoimmune tendencies, again pointing to the risks of cytokine interventions.
Janus kinase (JAK) inhibitors may be a particularly effective for treating the IFN-dominant 
inflammome, given the critical role of JAKs in IFN signaling (Table I). The expression 
specific JAK isotypes in different cell types provides an additional layer of specificity. 
Ruxolitinib has been developed as a JAK1 and JAK2 inhibitor, whereas tofacitinib is 
specific for the JAK3 isotype. Since JAK3 is predominantly expressed by hematopoietic 
lineage cells (including T cells and NK cells), JAK3 inhibitors can achieve some novel anti-
inflammatory effects. Recent clinical data have shown tofacitinib to be superior to 
methotrexate for the treatment of rheumatoid arthritis [41]. Inhibition of JAK2 by 
Ruxolitinib has side effects that limits its use, but has shown some effectiveness for treating 
myelofibrosis, a disease frequently driven by activating mutations in JAK2 [42]. Additional 
study of the JAK inhibitors could further establish their utility as part of a comprehensive 
treatment plan for the innate/IFN-driven inflammome.
2.3 INNATE (INFLAMMASOME DOMINANT)
The third major inflammome driven by innate immune cells centers on activation of 
inflammasomes, which are pentameric or heptameric protein complexes that serve to couple 
PAMP and DAMP sensing with the proteolytic cleavage of pro-IL-1β and pro-IL-18 via 
caspase 1 [43]. Several different inflammasomes exist and differ somewhat in structure, but 
each contains a PRR-like protein [a NOD-like receptor protein (NLRP) or the interferon-
inducible AIM2] connected to pro-caspase 1 by the adaptor protein ASC [44]. 
Inflammasomes also have been reported to confer resistance to different kinds of pathogens 
based on the PRR that is affiliated with them. For example, the NLRP3 inflammasome 
responds to Staphylococcus spp., Listeria spp., and influenza viruses, the NLRC4 
inflammasome is activated by intracellular pathogens bearing flagella, and the AIM2 
inflammasome responds to dsDNA from Francisella tularensis and herpes viruses [45, 46]. 
The exact nature of inflammasome activation and regulation are still active areas of 
investigation; however, several consensuses have been reached. First, inflammasomes 
usually require two signals in order to become fully responsive: 1) a signal is required to 
drive expression of substrates for the inflammasome (i.e. pro-IL-1β and pro-IL-18), which 
usually occurs in response to signaling cascades downstream of other PRRs and 2) the 
inflammasome requires a second signal that stimulates the cleavage of pro-caspase 1 into 
bioactive caspase 1, and subsequently the production of mature IL-1β and IL-18. There is 
much conjecture as to what can provide the second signal and present data point to 
intracellular potassium efflux [47], extracellular ATP sensing [48], exposure to lysosomal 
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enzymes like cathepsin B [49], and reactive oxygen species [50]. Following activation, 
inflammasome regulation is less well understood, but factors associated with chronic 
infection, such as prolonged IFNγ, exposure can lead to inflammasome destabilization 
through nitric oxidize-mediated nitrosylation [51].
The inflammasome dominant inflammome becomes medically relevant in response to 
bacterial and viral pathogens, but also in the context of situations involving “frustrated 
phagocytosis” which can result from exposure to particulate antigens. Diseases associated 
with the inflammasome dominant inflammome include gout (uric acid crystals), asbestosis 
(asbestos fibrils), berylliosis (beryllium), silicosis (silica), sarcoidosis, and amyloidosis 
(protein deposits) [52]. Each of these diseases lead to localized inflammation of the area 
where these particulates are deposited which is usually the lung (beryllium, silica, asbestos), 
joints (uric acid), or small blood vessels and soft tissue (amyloid). Inflammasomes are also 
implicated in both metabolic disease and atherosclerosis, and may be a central player in the 
development of insulin resistance in type-2 diabetes mellitus [53].
Antagonistic IL-1 therapies such as anakinra (receptor antagonist [54]), canakinumab (anti-
IL-1 mAb [55]), and rilonacept (soluble decoy receptor [56]) have proved efficacious in 
these types of diseases, including gout [57]. Many of these therapies were initially 
developed for the treatment of rheumatoid arthritis; however, they have shown limited long-
term efficacy in humans [58]. This illustrates that the presence of a particular cytokine 
within the inflammatory milieu in a given disease, and thus an attempt to block it 
therapeutically, is not necessarily sufficient to effectively decrease symptom severity. 
However, a full understanding of the inflammome of a given disease can better guide 
clinicians to more rational interventions.
With regard to the inflammasome inflammome, direct inflammasome inhibition is one 
obvious approach. Pre-clinical studies have supported the benefit of inflammasome 
inhibition for some inflammatory animal models. Interestingly, the IκB kinase-β inhibitor 
Bay-11-7082 was found to potently inhibit the NLRP3 inflammasome, most likely through 
inhibiting the NLRP3 ATPase activity [59]. Although studies with inhibitor are still at the 
preclinical stage, data showing efficacy for protection in a mouse model of diabetic 
nephropathy has been reported [59]. The selective deployment of newly developed 
inflammasome inhibitors in the clinic could therefore serve to control inflammation close to 
the root cause.
2.4 ADAPTIVE (T CELL CENTRIC)
T cells are perhaps the best studied of all immune cells due to their importance in mediating 
nearly every immune and inflammatory response [60]. T cells are activated after their T cell 
receptor (TCR) encounters a peptide antigen that has been processed and presented by an 
APC in the context of the major histocompatibility complex (MHC)[61]. Naïve T cells also 
require a second signal from co-stimulatory molecules, which together with the antigen 
signal, drives their proliferation (clonal expansion) via the production of IL-2 [62]. Co-
stimulation usually arises from the interaction between CD28 on the T cell and CD80/CD86 
on the APC; however, ligation of other co-stimulatory molecules such as ICOS, OX40, and 
4-1BB can also provide this necessary signal [15]. Finally, a third signal in the form of 
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cytokines directs differentiation of the activated T cell towards a specific effector subtype, 
and in some cases (IL-33) enhances their ability to produce effector cytokines. Thus, the T 
cell centric inflammome can take on different characteristics depending on the context in 
which it was induced. The major T cell subsets include Th1 (driven by IL-12, IL-18, 
IFNα/β), Th2 (IL-4, IL-33), Th17 (TGFβ & IL-1, IL-6, IL-21, IL-23), and T regulatory cells 
(TGFβ), but other, less well defined subsets also exist, including cytotoxic T helper cells, 
Th9, Th22, Tfh, and Tr1 [63, 64]. For the purpose of this review, we will focus on Th1, Th2, 
and Th17 subtypes, as they have been the best studied in the context of mediating human 
disease.
Th1 T cells are produced when activated in the context of IL-12, IL-18, and Type-I IFNs 
and the absence of IL-4 [65]. They are defined by the major transcription factor T-bet which 
is necessary for their ability to produce the effector cytokine IFNγ. Th1 T cells also provide 
help to CD8+ cytotoxic T lymphocytes (CTLs) that respond to cells infected with 
intracellular pathogens or expressing altered self-antigens (cancerous cells), and kill them by 
production of several soluble effector molecules including IFNγ, granzymes, granulysin, and 
perforin [66]. CTLs can also induce death through contact-mediated, caspase 8 dependent 
apoptosis by Fas-FasL (CD95-CD95L) and TNF-related apoptosis-inducing ligand 
(TRAIL)-DR5 [67]. Th1 cells have been implicated in the pathogenesis of numerous 
autoimmune diseases through inappropriate activation by self-antigens. They can also 
potentiate the innate immune response through the positive feedback effects of IFNγ.
Th17 T cells are produced in the context of TGFβ and other pro-inflammatory cytokines 
such as IL-6, IL-1β, IL-21, IL-23, and others [68]. Their differentiation to Th17 can be 
enhanced through the autocrine production of IL-21, and are stabilized by IL-23 after the up-
regulation of IL-23R following TCR activation [69]. Th17 polarization is controlled by the 
master transcription factor RORγT/RORC2 [70], which facilitates IL-17A, IL-17F, IL-21, 
and IL-23 production from Th17 T cells [71]. A major function of IL-17 is to recruit 
neutrophils to the sites of infection by stimulating the production of CXCL8, CCL2, CCL7, 
CXCL1, and CXCL5 [72]. IL-17 can also promote synthesis of TNF, IL-6, and IL-1β from 
epithelial cells and macrophages. Th17 cells have been implicated as pathogenic in mouse 
models of RA, IBD, psoriasis, and type-1 diabetes mellitus, as well as several diseases in 
humans: multiple sclerosis, RA, SLE, psoriasis, and IBD [73]. These associations have been 
largely based on finding elevated IL-17 levels in either sera or tissue biopsies from afflicted 
patients, or the direct visualization of Th17 cells within diseased tissue biopsies [74]. 
Several therapies that target the Th17 pathway are available or under development, 
including a monoclonal antibody called ustekinumab that targets the IL-12p40 subunit 
shared by IL-12 and IL-23 [75], and several anti-IL17 antibodies that are not yet FDA 
approved (brodalumab, ixekizumab, and secucinumab). Ustekinumab treatment has seen 
some success in treating patients with psoriasis, but that success has not translated to other 
Th17 implicated diseases to date [76, 77].
The final T cell subset that can define a T cell centric inflammome are the Th2 T cells that 
differentiate in the presence of IL-4 or IL-33 and the absence of IFNγ [78, 79]. Th2 cells are 
potent promoters of IL-4, IL-5, and IL-13 production and are defined by their master 
transcription factor GATA3. Th2 cells can also efficiently stimulate B cell expansion 
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through CD40-CD40L interactions. In the presence of IL-4, B cells secrete antibodies of the 
IgE isotype, which are critical for protection against helminthic infection, but can also drive 
allergic responses in humans [80]. The concomitant actions of IgE binding to its receptor 
(FcεRI) and the Th2-associated cytokines potently induce granulocyte chemotaxis and the 
degranulation of mast cells, eosinophil, and basophils. This degranulation releases 
vasoactive amines (e.g. histamine), serine proteases, and eicosanoids (such as prostaglandins 
and leukotrienes), all of which trigger allergic symptoms (erythema, pruritus, 
bronchoconstriction) [81]. Once again, most therapies currently approved for treatment of 
allergic reactions are typically based on post hoc approaches. These interventions involve 
the blockade of histamines and leukotrienes, or management of symptoms through the use of 
bronchodilators [82]. Investigation into blocking these responses at the level of T cell (or B 
cell) initiation is an area that requires attention.
The T cell centric inflammome can assume very diverse outcomes, and be the driving force 
behind many different types of inflammatory diseases. However, because T cells undergo 
clonal expansion in response to activation, they are susceptible to many of the broadly 
immunosuppressive agents that kill dividing cells [83]. For example, corticosteroids block 
the production of IL-2, and immunophilins (such as tacrolimus and cyclosporine) prevent 
calcineurin-mediated activation of NFAT, a transcription factor critical for T cell responses 
[84]. Also, cyclostatic drugs (e.g. methotrexate, azathioprine, mercaptopurine) that block all 
cell proliferation, and are typically used in cancer therapy, are sometimes used to prevent T 
cell expansion in inflammatory diseases [85]. All of these therapeutic options prevent pro-
inflammatory cytokine production; however, they also suffer from lack of specificity. Future 
studies aimed at improving T cell-based therapeutic interventions should seek to combine 
the a priori blockade of cytokine synthesis with the specificity of a biologic treatment in 
order to prevent complications associated with broad immunosuppression.
One potential example of this a priori cytokine inhibition strategy is blockade of Raf 1 
kinase inhibitor protein (RKIP) by the small molecule inhibitor locostatin. RKIP has been 
implicated as an important signaling molecule in both the NF-κB and MAPK signaling 
cascades [86, 87]. Although the exact molecular mechanism by which RKIP functions in 
vivo remains elusive, it is preferentially activated in recalled T cells and its inhibition by 
locostatin can significantly attenuate the production of IFNγ from antigen-specific CD8+ 
effector T cells in a T-cell dependent model of SIRS [88], as well as IFNγ and TNF 
synthesis from human flu specific CTLs and LPS stimulated PBMCs [89]. Identification and 
development of other agents that target over-active signaling pathways in activated T cells 
could enable clinicians to suppress T cell inflammomes prior to the excessive expression of 
cytokines.
2.5 ADAPTIVE (B CELL CENTRIC)
The main effectors of the B cell centric inflammome are antibodies, which are generated 
after the integration of signals from B cell receptor ligation, T cell help, PRR signaling, and 
the cytokine milieu [90]. The effector functions of antibodies are well defined and include 
opsonization and neutralization of pathogens, initiation of the complement cascade, and 
activation of other effector cells. Different antibody isotypes are generated by activation-
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induced cytodine deaminase (AICD) in response to sensing the cytokine milieu by B cells. 
For example, in humans the presence of IFNγ will trigger production of IgG1 whereas IL-4 
will promote IgE production and TGFβ will yield IgA [91].
B cells can also be significant contributors to cytokine synthesis in their own right. B cells 
that are primed by Th1 cells and BCR ligation will begin to produce a “Th1-like” cytokine 
profile including synthesis of IFNγ and even IL-12, a cytokine not made explicitly by Th1 
cells but key for Th1 differentiation (B effector type 1 or Be-1 cells). By analogy, those 
primed with Th2 cells will produce IL-2, IL-4, and IL-13 (Be-2 cells) [92]. Additionally, B 
cells can also produce regulatory cytokines, such as TGFβ and IL-10, in some circumstances 
(Bregs). Each of the B cell cytokine-producing subtypes have been identified in vivo [93], 
and have documented functional significance, especially in the context of pathogen 
clearance and autoimmune diseases that result from the inappropriate production of 
autoantibodies like SLE and many others [94]. Nevertheless, much remains to be studied 
regarding the role of B cell generated cytokines in inflammatory disorders.
2.6 REVERSE-PHASE IMMUNITY
Recently, more evidence is coming to light that exemplifies the bi-directionality of the 
immune response, in that exposure to molecules that directly activate T cells, such as 
superantigens, can lead to T-cell mediated activation of the innate immune system [95]. This 
concept outlines an emerging reverse-phase inflammome that relies on bystander activation 
of the innate immune response through cytokines produced by the adaptive arm of the 
immune system, rather than PAMP or DAMP exposure. The exact mechanism(s) by which 
this activation occurs is still an area of active investigation; however, production of IL-17 by 
TCRγδ T cells after cooperative activation by TCRαβ T cells has been implicated [96, 97]. 
This novel route of innate immune system activation will generate an inflammatory-milieu 
that is largely similar to those generated by the innate inflammomes discussed above. In 
cases such as Staphyloccal enterotoxin A (SEA) mediated acute lung injury or SIRS, a 
physician may see a cytokine profile that implicates the innate immune system as the main 
driving force in disease pathogenesis; however, treating such a disease with therapeutics 
such as anti-TNF may not be productive because the actual pathogenic mechanism is 
directed by T cells. In this instance a better outcome would be obtained using agents that 
target IL-17 or IL-2 production. Although a cytokine-based disease taxonomy allows for a 
better understanding of how to treat diseases that share related milieus, it may in some cases 
lead clinicians to incorrect assumptions that could be insignificant, or even deleterious to the 
patient. An understanding of a patient’s underlying inflammome would enable physicians to 
administer targeted and timely therapeutic interventions, which could improve a patient’s 
condition with fewer side-effects.
3.0 CONCLUSIONS
Inflammation is one of our body’s greatest assets as it is responsible for the defense against 
harmful pathogens and facilitates removal and repair of dead or dying cells. However, 
inflammation is also the pathogenic mechanism by which many diseases are manifest, 
leading to significant medical and financial burdens for patients. Our ability to 
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therapeutically intervene in these pathophysiological processes is key to preventing undue 
morbidity and mortality in these patients. Before the 1990s, the standard of care for many 
auto-inflammatory diseases involved broad immunosuppression using corticosteroids or 
direct killing of proliferating cells, both of which lead to significant immunosuppression and 
the inability to ward off potential infections. With the advent of cytokine-specific biologics, 
clinicians and scientific investigators became much more interested in specific, targeted 
therapies that attenuated disease, while allowing for most of the immune response to 
continue unabated. This led many to consider a disease diagnostic schema that centered on a 
particular cytokine milieu. This has resulted in the development of successful therapeutic 
endeavors for some diseases (IBD, RA), but also to significant failures (anti-TNF in MS, 
anti-IL-1 in sepsis, and anti-IL-17 in Crohn’s disease) [98-100]. These failures are due in 
large part to the exclusive focus on post hoc cytokine production rather than an examination 
of the underlying inflammome that led to the generation of these cytokines in the first place. 
By understanding the inner workings of the body’s different inflammomes, better therapies 
can be developed that stop altered cytokine production at the source, rather than treating 
them as the sole cause of the disease.
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Figure 1. An Inflammome-based Disease Taxonomy
A schematic representation of the cytokine networks established by the host’s major 
inflammomes; the size of each circle pictorially represents the relative abundance of a given 
cytokine within its respective inflammome. Human diseases associated with each 
inflammome are listed in non-bold script.
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TABLE I
Examples of a priori Inflammome Inhibitors Currently Under Investigation
Drug Mechanism of Action Point inPipeline
Inflammome
Affected
Potential Diseases
Interventions
Apremilast (Otezla)
GSK256066 PDE4
*
 inhibitor- ↑ PKA ↓ NF-κB Approved
†
Phase 2
Innate TNF &
Inflammasome
dominant
Psoriatic Arthritis
Ankylosing Spondylitis
Allergic Rhinitis
Atreleuton (VIA-2291) 5-LO** inhibitor- ↓ Leukotrienes Phase 2
T cell centric
(Th2) & B cell
centric (Be2)
Allergy, Atherosclerosis,
Vasculitis
Apilimod (STA-5321) PIKfyve inhibitor- ↓ IL-12 ↓IL-23 Phase 1 T cell centric(Th1/Th17) Inflammatory Bowel Disease
Dilmapimod (SB-681323)
Losmapimod (GW856553X)
BMS-582949
p38 MAPK inhibitor- pleiotropic
Phase 1
Phase 2
Phase 2
Multiple
COPD
Rheumatoid Arthritis
Atherosclerosis
Diacerein Xanthine Oxidase inhibitor - ↓IL-1β Phase 4
Innate
Inflammasome
dominant
Gout
Resatorvid (TAK-242) TLR4 inhibitor Phase 3
Innate TNF &
Inflammasome
dominant
Sepsis, ARDS
Tofacitinib (CP-690550)
Ruxolitinib (INC424) Janus Kinase (JAK) Inhibitors‡ Phase 3
Innate & Adaptive
Inflammomes
Rheumatoid Arthritis,
Psoriasis, Myelofibrosis,
Leukemia
BAY-11-7082
Inhibits TNFα induced IκB-α
phosphorylation & NLRP3
inflammasome
Pre-clinical
Innate TNF &
Inflammasome
dominant
Diabetic Neuropathy
Cardiac Ischemia-Reperfusion
Locostatin RKIP inhibitor- ↓ IFNγ ↓IFNα Pre-clinical
T cell centric
(Th1) & Innate
IFN dominant
SIRS
*
Phosphodiesterase 4
**5-Lipoxygenase
†
FDA approval for Psoriatic Arthritis (March 2014)
‡
Provide both a priori and post hoc inhibition due to prevention of cytokine-induced cytokine release
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